Tissue Transglutaminase Test Market Research Report- Global Forecast till 2027

Tissue Tranglutaminase (Ttg) Test Market: By Type (Serological, Biopsy, and others), and By End Users (Hospitals & Clinics, Homecare, Research Organisations, others) - Global Forecast Till 2027

ID: MRFR/LS/0328-HCR | February 2021 | Region: Global | 81 pages

Please note that the assessment period of report has been updated from 2017–2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Synopsis of Global Tissue Transglutaminase (tTG) Test Market Market scenario Tissue transglutaminase (tTG) test is used for the diagnosis of certain autoimmune diseases, which is mostly restricted to celiac disease. In celiac disease, gluten (a protein found in wheat, barley, rye, and oats) is seen as a foreign invader and is attacked by the immune system. This is followed by the production of antibodies directed against the enzyme Tissue Transglutaminase (tTG) (a calcium dependent proteolysis restricting enzyme), which is normally present in intestines. Immunoglobulin A (IgA) and immunoglobulin G (IgG) are the antibodies responsible for the autoimmune responses. These (tTG) IgA and (tTG) IgG can be analyzed for diagnostic purposes. The IgA form of tTG antibody is more frequently exploited for the diagnosis of celiac disease because it is synthesized in the small intestine where gluten causes inflammation and irritation in sensitive people. On the other hand, (tTG) IgG can also be used. Its application in testing is marked when patient is unable to produce normal IgA as it is less specific to celiac disease. Traditionally, mucosal biopsies can be performed.

The major factor that propels the global tissue transglutaminase testing market is the increasing prevalence of celiac disease. According to the World Gastroenterology Organization in 2016, 1% of the total population in western countries was diagnosed with the celiac disease and the prevalence have substantially increased across the globe. According to Celiac Disease Foundation in 2016, hospitalization have increased by 600% from 1998 to 2013 in the U.S. Similar trends in the European countries are observed. All these factors will boost the global tissue tranglutaminase (tTG) testing market.     

Increasing prevalence of autoimmune diseases mainly celiac disease, increasing geriatric global pool, and increasing investments in the healthcare drive the growth of the market. Low healthcare expenditure in developing regions, costs considerations, and false positive diagnosis in geriatric population marked due to conditions such as diarrhoea etc restrain the growth of the market.

The market is expected to grow at a CAGR of 17.5% during the forecast period.

Research Methodology Tissue Transglutaminase Test Market

Intended Audience

  • Antibody manufacturers & suppliers

  • Research and development (R&D) companies

  • Hospitals and clinics

  • Academic institutes and universities

Figure 1           Global Tissue Transglutaminase Testing Market by Region, 2016 (% market share) Tissue Transglutaminase Test Market-

Segments The global tissue transglutaminase testing market has been segmented on the basis types and end users.

Based on types, the market has been segmented into serological testing, biopsy, and others. The serological testing is sub-segmented into tissue transglutaminase (tTG) antibody- IgA, serum and Tissue Transglutaminase (tTG) antibody-IgG, serum, and others.

Based on the end users, the market has been segmented as hospitals & clinics, homecare, research organizations, and others. Regional analysis The Americas account for a significant market share owing to extensive use of medications and high expenditure on the health care. Additionally, the fastest uptake of new technology in the US drives the tTG testing market. Also, concentration of major research companies and research organizations in the developed countries of this region add fuel to the market growth.

Europe is the second largest market in the world due to high income and high healthcare penetration.

Asia Pacific region is expected to grow rapidly over the forecast period and China and India are likely to lead this market due to the fast growing healthcare sector.

Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development during the review period. Key Players in the Global Tissue Transglutaminase(tTG) Testing Market

Some of the key players profiled in the report are Quest Diagnostics Incorporated., SQI Diagnostics, Trinity Biotech, ZEDIRA GmbH, Demeditec Diagnostics GmbH, ARUP Laboratories, Cell Science Systems, and Bio-Rad Laboratories, Inc., Pfizer Inc., Celimmune, LLC.,  and others.   

The report for Global Tissue Transglutaminase Testing Market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.

Frequently Asked Questions (FAQ) :

Tissue tranglutaminase (TTG) test market CAGR would be 17.5% during the forecast period.

The end users included in the tissue tranglutaminase (TTG) test market report are homecare, research organizations, hospitals & clinics, and others.

Tissue tranglutaminase (TTG) test market types are serological testing, biopsy, and others.

Tissue tranglutaminase (TTG) test market report includes players like SQI Diagnostics, Quest Diagnostics Incorporated., ZEDIRA GmbH, Cell Science Systems, Trinity Biotech, ARUP Laboratories, Demeditec Diagnostics GmbH, and Bio-Rad Laboratories, Inc., Pfizer Inc., Celimmune, LLC., and others.

Europe would be the second-largest tissue tranglutaminase (TTG) test market.